Obseva Logo highresolution.jpg
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at ASRM 2021 Scientific Congress & Expo
October 20, 2021 01:00 ET | ObsEva SA
-Final results from pilot study of linzagolix for the treatment of severe adenomyosis to be presented in a second poster -   Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss...
Obseva Logo highresolution.jpg
ObsEva Announces Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at ASRM 2021 Scientific Congress & Expo
October 19, 2021 01:00 ET | ObsEva SA
–Presentation of Phase 3 clinical data on linzagolix for the treatment of uterine fibroids and final results from a pilot study of linzagolix for the treatment of severe adenomyosis– GENEVA,...
Inherent Biosciences Launches Path Fertility - Epigenetic Sperm Quality Test (SpermQT)
October 18, 2021 09:12 ET | Inherent Biosciences Inc
SALT LAKE CITY, Oct. 18, 2021 (GLOBE NEWSWIRE) --  Inherent Biosciences, a molecular diagnostics company at the intersection of epigenetics and artificial intelligence (AI), today announced the...
Obseva Logo4 (00000002).jpg
ObsEva SA Presented Two Late-Breaking Posters at the ASRM 2020 Virtual Scientific Congress October 17-21
October 22, 2020 01:00 ET | ObsEva SA
  Geneva, Switzerland and Boston, MA – October 22, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s...
Obseva Logo4 (00000002).jpg
ObsEva SA Presented Nolasiban Poster at the ASRM 2020 Virtual Scientific Congress October 17-21
October 20, 2020 01:00 ET | ObsEva SA
  Geneva, Switzerland and Boston, MA – October 20, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s...
logo_new.jpg
ObsEva SA to Present New Clinical Data on its Lead Compounds Nolasiban and Linzagolix at the 75th Annual ASRM Meeting in Philadelphia, PA
October 09, 2019 01:00 ET | ObsEva SA
Geneva, Switzerland and Boston, MA –October 9, 2019- ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss  clinical-stage biopharmaceutical company focused on the development and commercialization of...
logo_new.jpg
ObsEva SA Presents Clinical Data from Phase III IMPLANT 2 Trial of Nolasiban in IVF at the American Society of Reproductive Medicine (ASRM) Annual Meeting
October 09, 2018 16:15 ET | ObsEva SA
Abstract featuring-IMPLANT2 data awarded Prize Paper by Society for Assisted Reproductive Technology (SART)  Nolasiban treatment shown to significantly increase Live Birth Rate (LBR) in...
logo_new.jpg
ObsEva SA Announces Phase 3 IMPLANT 2 Clinical Trial Results of Nolasiban in IVF to be Presented at Annual ASRM Meeting Tuesday October 9, 2018
October 05, 2018 01:00 ET | ObsEva SA
Recipient of Prize Paper Award from the Society for Assisted Reproductive Technology (SART) Geneva, Switzerland and Boston, MA - October 5, 2018- ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a...
Progyny Stacked RGB 72.jpg
Progyny Expands its Clinical Leadership, adding Alan B. Copperman, M.D., FACOG as Medical Director
October 02, 2017 09:30 ET | Progyny
NEW YORK, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Progyny, the leading fertility benefits company, today announced that Alan B. Copperman, M.D., FACOG has joined the Company as Medical Director. In his...